Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of kaempferol in preparation of anti-HCV (hepatitis c virus) infective medicaments

A technology of kaempferol and medicine, which is applied in the application field of kaempferol in the preparation of anti-HCV infection drugs, and achieves the effects of small toxic and side effects, wide sources, and mature purification process

Inactive Publication Date: 2015-01-28
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] There is no literature report on the relationship between kaempferol and hepatitis C virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kaempferol in preparation of anti-HCV (hepatitis c virus) infective medicaments
  • Application of kaempferol in preparation of anti-HCV (hepatitis c virus) infective medicaments
  • Application of kaempferol in preparation of anti-HCV (hepatitis c virus) infective medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Kaempferol dose-dependently inhibits HCV, EC50 is 1.459 μM, CC50 is greater than 100 μM:

[0029] 1. Experimental method:

[0030] 1. Experimental cell line: Huh7.5 cells (human liver cancer cells). It comes from the laboratory of Professor Chen Zhili, a chemical engineer in Texas, USA.

[0031] 2. Plasmid for experiment: Jc1FLAG (p7-nsGluc2A plasmid is from Rockefeller University, New York, USA.

[0032] 3. Experimental reagents, consumables and instruments: DMEM culture medium (Invitrigen), DPBS (Thermo Scientific HyClone), CellTiter-Glo cell viability assay kit (Promega), BioLux Gaussia luciferase assay kit (New England BioLabs (Ipswich , MA). NS5A monoclonal antibody 9E10 was from The Rockefeller University, USA. ECM 830 electroporator (Harvard Apparatus), pipette (VWR), 96-well culture plate (VWR).

[0033] 4. Experimental drugs:

[0034] Medicine of the present invention: kaempferol (kaempferol, KP)

[0035] Negative control drug: DMSO (sigma)

[...

Embodiment 2

[0044] Example 2: Kaempferol exerts anti-HCV activity by inhibiting the replication stage of HCV

[0045] 1. Experimental method:

[0046] The HCV life cycle includes the stages of virus entry, replication, packaging and cell secretion, etc. In order to explore how kaempferol inhibits HCV replication, we applied the inhibition experiment of HCV replication and infectious virus production based on luciferase detection and the HCV pseudo The inhibition mechanism of kaempferol was studied by virus (HCVpp) cell entry inhibition experiment.

[0047] 1. Cell lines used in the experiment: 293T cells (human kidney epithelial cells) and Huh7.5 cells (human liver cancer cells). It comes from the laboratory of Professor Chen Zhili, a chemical engineer in Texas, USA.

[0048] 2. Experimental plasmids: HIV Gag-Pol (AIDS virus membrane protein encoding plasmid), HCV H77 / J6 (hepatitis C virus encoding plasmid), VSV (vesicular stomatitis virus membrane protein encoding plasmid) and Jc1FLAG ...

Embodiment 3

[0063] Example 3: Kaempferol can inhibit HCV replication at gene level and protein level

[0064] 1. Experimental method:

[0065] In order to clarify whether kaempferol (KP) has the same inhibitory effect on HC at the gene level and protein level, we used Western blot (western blot) and real-time fluorescent quantitative PCR (qRT-PCR) to investigate the inhibitory effect of KP on HCV. studied.

[0066] 1. The cell line used in the experiment: Huh7.5 cells (human liver cancer cells), from the laboratory of Professor Chen Zhili of Chemical Engineering in Texas, USA.

[0067] 2. Experimental plasmid: Jc1FLAG (p7-nsGluc2A plasmid is from Rockefeller University, New York, USA. 3. Experimental reagents, consumables and instruments: DMEM culture medium (Invitrigen), DPBS (Thermo Scientific HyClone), CellTiter-Glo cell viability detection kit ( Promega), BioLux Gaussia Luciferase Assay Kit (New England BioLabs (Ipswich, MA). Renilla Luciferase Lysis Buffer (Promega), 2ⅹ SDS Loading...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine and provides the application of kaempferol in preparation of anti-HCV (hepatitis c virus) infective medicaments. Kaempferol is called KP for short, is a flavonoids compound, and widely exists in various fruits and traditional Chinese medicines such as gingko, propolis, tilia amurensis and Chinese scholartree. The experiment verifies that kaempferol can inhibit HCV replication in terms of protein level and RNA level, is dose-dependent, can inhibit replication of HCV of different gene types, has a synergistic effect with IFN, can inhibit acute and chronic HCV infection, and meanwhile can obviously inhibit inflammatory factor RNA expression induced by an HCV core antigen and an NS5A antigen, especially the epoxidase 2 gene expression.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of kaempferol in the preparation of anti-HCV infection drugs. Background technique [0002] Hepatitis C virus (HCV for short) is one of the important causes of chronic viral hepatitis worldwide. Long-term occult infection of HCV may lead to advanced liver diseases such as liver fibrosis, liver cirrhosis and liver cancer. The combination of interferon and ribavirin is widely used in the treatment of HCV infection, but this therapy has limited therapeutic effect and has many side effects. The emergence of HCV small molecule direct antiviral drugs (DAAs) has greatly improved the therapeutic effect and is expected to eventually completely replace interferon therapy. However, entering the era of DAA in the treatment of chronic hepatitis C does not mean that the problem of hepatitis C has been solved, so different treatment strategies need to be explored. [0003] T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P31/14
CPCA61K31/352A61K2300/00
Inventor 梁雪松张卫东单磊
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com